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1. Introduction 
An overview of translational, human oncogenomics, transcriptomics and cancer 
interactomic networks is presented together with basic concepts and potential, new 
applications to Oncology and Integrative Cancer Biology. Novel translational oncogenomics 
research is rapidly expanding through the application of advanced technology, research 
findings and computational tools/models to both pharmaceutical and clinical problems. A 
self-contained presentation is adopted that covers both fundamental concepts and the most 
recent biomedical, as well as clinical, applications. Sample analyses in recent clinical studies 
have shown that gene expression data can be employed to distinguish between tumor types 
as well as to predict outcomes. Potentially important applications of such results are 
individualized human cancer therapies or, in general, ‘personalized medicine’. Several cancer 
detection techniques are currently under development both in the direction of improved 
detection sensitivity and increased time resolution of cellular events, with the limits of 
single molecule detection and picosecond time resolution already reached. The urgency for 
the complete mapping of a human cancer interactome with the help of such novel, high-
efficiency, low-cost and ultra-sensitive techniques is also pointed out. 
1.1 Current status in translational genomics and interactome networks 
Upon completion of the maps for several genomes, including the human genome, there are 
several major post-genomic tasks lying ahead such as the translation of the mapped 
genomes and the correct interpretation of huge amounts of data that are being rapidly 
generated, or the important task of applying these fundamental results to derive major 
benefits in various medical and agricultural biotechnology areas. Translational genomics is 
at the center of these tasks that are running from transcription through translation to 
proteomics and interactomics. The transcriptome is defined as the set of all ‘transcripts’ or 
messenger RNA (mRNA) molecules produced through transcription from DNA sequences 
by a single cell or a cell population. This concept is also extended to a multi-cellular 
organism as the set of all its transcripts. The transcriptome thus reflects the active part of the 
genome at a given instant of time. Transcriptomics involves the determination of mRNAs  
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expression level in a selected cell population. For example, an improved understanding of cell 
differentiation involves the determination of the stem cell transcriptome; understanding 
carcinogenesis requires the comparison between the transcriptomes of cancer cells and 
untransformed (‘normal) cells. However, because the levels of mRNA are not directly 
proportional to the expression levels of the proteins they are encoding, the protein 
complement of a cell or a multi-cellular organism needs to be determined by other techniques, 
or combination of techniques; the complete protein complement of a cell or organism is 
defined as the proteome. When the network (or networks) of complex protein-protein 
interactions (PPIs) in a cell or organism is (are) reconstructed, the result is called an interactome. 
This complete network of PPIs is now thought to form the ‘backbone’ of the signaling 
pathways, metabolic pathways and cellular processes that are required for all key cell 
functions and, therefore, cell survival. Such a complete knowledge of cellular pathways and 
processes in the cell is essential for understanding how many diseases -- such as cancer (and 
also ageing) —originate and progress through mutation or alteration of individual pathway 
components. Furthermore, determining human cancer cell interactomes of therapy-resistant 
tumors will undoubtedly allow for rational clinical trials and save patients’ lives through 
individualized cancer therapy. Since the global gene expression studies of DeRisi et al in 1997, 
translational genomics is very rapidly advancing through the detection in parallel of mRNA 
levels for large numbers of molecules, as well as through progress made with miniaturization 
and high density synthesis of nucleic acids on microarray solid supports. Gene expression 
studies with microarrays permit an integrated approach to biology in terms of network 
biodynamics, signaling pathways, protein-protein interactions, and ultimately, the cell 
interactome. An important emerging principle of gene expression is the temporally coordinated 
regulation of genes as an extremely efficient mechanism (Wen et al 1998) required for complex 
processes in which all the components of multi-subunit complexes must be present/available 
in defined ratios at the same time whenever such complexes are needed by the cell. The gene 
expression profile can be thought of either as a ‘signature/ fingerprint’ or as a molecular 
definition of the cell in a specified state (Young, 2000). Cellular phenotypes can then be inferred 
from such gene expression profiles. Success has been achieved in several projects that profile a 
large number of biological samples and then utilize pattern matching to predict the function of 
either new drug targets or previously uncharacterized genes; this ‘compendium approach’ has 
been demonstrated in yeast (Gray et al 1998; Hughes et al 2000), and has also been applied in 
databases integrating gene expression data from pharmacologically characterized human 
cancer lines (NCI60, http://dtp.nci.nih.gov), or to classify cell lines in relation to their tissue of 
origin and predict their drug resistance or chemosensitivity (Weinstein et al, 1997; Ross et al 
2000, Staunton et al 2001). Furthermore, sample analyses in clinical studies have shown that 
gene expression data can be employed to distinguish between tumor types as well as to 
predict outcomes (Golub et al 1999; Bittner et al, 2000; Shipp et al 2002; Furteal et al., 2004). The 
latter approach seems to lead to important applications such as individualized cancer therapy 
and ‘personalised medicine’. On the other hand, such approaches are complemented by 
studies of protein-protein interactions in the area called proteomics, preferably under 
physiological conditions, or more generally still, in cell interactomics. Several technologies in 
this area are still developing both in the direction of improved detection sensitivity and time 
resolution of cellular events, with the limits of single molecule detection and picosecond time 
resolution already attained. In order to enable the development of new applications such 
techniques will be briefly described in the next section, together with relevant examples of 
their recent applications. 
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1.2 Basic concepts in transcription, translation and interactome networks 
The analysis of bionetwork dynamics of protein synthesis considered as a channel of 
information operates through the formation of protein amino acid sequences of 
polypeptides via translation of the corresponding polynucleotide sequences of (usually 
single –stranded, messenger) ribonucleic acid, that is: 
DNA (gene) transcription  mRNA  translation into a polypeptide‘s aminoacid sequence 
 protein (quaternary) assembly from polypeptide subunits. 
Although not shown in this scheme, several key enzymes make such processes both efficient 
and precise through highly-selective catalysis; moreover, the protein assembly involves both 
specific enzymes and ribosome ‘assembly lines’. Furthermore, such processes are 
compartmented in the mammalian cells by selective intracellular membranes; this seems to 
be also important for cell cycling and the control of cell division. On the other hand, the 
reverse transcription, RNA DNA, does also occur (under certain conditions), catalized by a 
reverse transcriptase that contains both polypeptide chains and an RNA (master) strand. If 
error free, the first of these two sequence of processes —which are of fundamental biological 
importance-- generates true replicas of the information contained in the sense codons of the 
genes that are transcribed into mRNA anti-codons. Recall also that DNA stores information 
in the neucleotide bases A (Adenine), C (Cytosin), G (Guanine) and T (Thymine), and that a 
triplet of such nucleotides in the DNA sequence is called a codon, which may encode 
unambiguously just the information necessary to specify a single amino acid. Moreover, the 
genetic code is quasi-universal, and capable of ‘reverse transcription' from certain types of 
RNA back into DNA. Notably also, not all nucleotide or codon sequences present in the 
genome (DNA) are transcribed in vivo. Typically only a small percentage is transcribed. The 
transcribed (mRNA) sequences form what is naturally called the transcriptome; the protein--
encoded version of the transcriptome is called the proteome, and upon including all protein--
protein interactions for various cellular states one obtains the (global) interactome network. 
More generally, biological interactive networks as a class of complex bionetworks consist of 
local cellular communities (or ‘organismic sets') that are organized and managed by their 
characteristic selection procedures. Thus, in any partitioning of the organismal, or cell, 
structure, it is often necessary to regulate the local properties of the organism rather than the 
global mechanism, which explains an organism's need for specialized, ‘modular 
constructions'. Such a modular, complex system biology approach to modeling signaling 
pathways and modifications of cell-cycling regulatory mechanisms in cancer cells was 
recently reported (Baianu, 2004); several consequences of this approach were also 
considered for the proteome and interactome networks in a ‘prototype’ cancer cell model 
(Prisecaru and Baianu, 2005). Note, on the other hand, that there seem to be also present in 
the living cell certain proteins and enzymes that are involved in global intra-cellular 
interactions which are thought to be essential to the cell survival and cell’s flexible adaptation 
to stresses or challenge. Recent modeling techniques draw from a variety of mathematical 
sources, such as: topology (including graph theory), biostatistics, stochastic differential 
equations, Boolean networks, and qualitative system dynamics (Baianu, 1971a; de Jong et al 
2000; 2003, 2004). Non--boolean network models of genetic networks and the interactome 
were also developed and compared with the results of Boolean ones (Baianu, 1977, 1984, 1987; 
Georgescu, 2006; Baianu, 2005; Baianu et al. 2006). The traditional use of comparatively rigid 
Boolean networks (reviewed extensively, for example in Baianu, 1987) can be thus extended 
through flexible, multi--valued (non--Boolean) logic algebra bionetworks with complex, non-
linear dynamic  behaviors that mimic complex systems biology (Rosen, 2000).  
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The results obtained with such non--random genetic network models have several important 
consequences for understanding the operation of cellular networks and the formation, 
transformation and growth of neoplastic network structures. Non--boolean models can also 
be extended to include epigenetic controls discussed in Section 6, as well as to mimic the 
coupling of the genome to the rest of the cell through specific signaling pathways that are 
involved in the modulation of both translation and transcription control processes. The latter 
may also provide novel approaches to cancer studies and, indeed, to developing 
‘individualized’ cancer therapy strategies and novel anti-cancer medicines targeted at specific 
signaling pathways involved in malignant tumors resistance to other therapies. 
2. Techniques and application examples 
2.1 DNA microarrays 
DNA microarray technology is widely employed to monitor in a single experiment the gene 
expression levels of all genes of a cell or an organism. This includes the identification of 
genes that are expressed in different cell types as well as the changes in gene expression 
levels caused, for example, by differentiation or disease. The terabytes of data thus obtained 
can provide valuable clues about the interactions among genes and also about the 
interaction networks of gene products. It has been reported that cDNA arrays were 
pioneered by the Brown Laboratory at Stanford University (Brown and Botstein, 1999; URL: 
http://cmgm.stanford.edu/pbrown/mguide/index.html). Several quantitative and high-
density DNA array applications were then reported in rapid succession (Schena et al 1995; 
Chee et al 1996; Brown and Botstein, 1999). Such microarrays are generated by automatically 
printing double-stranded cDNA onto a solid support that may be either glass silicon or 
nylon. The essential technologies involved are robotics and devlopment/selection of 
sequence-verified and array-formatted cDNA clones. The latter ensures that both the 
location and the identity of each cDNA on the array is known. Sequence-verified and array-
formatted cDNA clone sets are now available from companies such as Incyte Genomics 
(Palo Alto, CA; URL: http://www.synteni.com/) and Research Genetics (Huntsville, AL; 
URL: http://www.resgen.com/). In cDNA-based gene expression profiling experiments, 
the total RNA is extracted from the selected experimental samples and the RNA is 
fluorescently labeled with either cye3- or cye5-dUTP in a single round of reverse 
transcription. The latter have several advantages: they are readily incorporated into cDNA 
by reverse transcription, they exhibit widely separated excitation and emission spectra, and 
also they possess good photostability. Such fluorescently--labeled cDNA probes are then 
hybridized to a single array through a competitive hybridization reaction. Detection of 
hybridized probes is achieved by laser excitation of the individual fluorescent markers, 
followed by scanning using a confocal scanning laser microscope. The raw data obtained 
with a laser scanning systems is represented as a normalized ratio of cye3: cye5 and 
automatically color coded; thus, red color is conventionally selected to represent those genes 
that are transcriptionally upregulated in the test versus the reference, whereas green color 
represents genes that are downregulated; those genes that exhibit no difference between test 
and reference samples are shown in yellow. The analysis of the gene expression data 
obtained by such a high throughput microarray technology is quite complex and requires 
advanced computational/bioinformatics tools as already discussed in Section 1.2. Other 
aspects related to interactomics are discussed in Section 3. An alternative technology to 
cDNA microarrays is discussed in the next section. 
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2.2 Oligonucleotide arrays 
By combining oligonucleotide synthesis with photolithography it was possible to synthesize 
specific oligonucleotides with a selected orientation onto the solid surface of glass or silicon 
chips (Lockhart et al 1996; Wodicka L, et al 1997), thus forming oligonucleotides arrays. The 
expression monitoring was then carried out by hybridization to high-density 
oligonucleotide arrays (Lockhart et al 1996; Wodicka L, et al 1997). Commercially available 
oligonucleotides array products include human, mouse and several other organisms. Each 
gene included on the oligonucleotides array is represented by up to 20 different 
oligonucleotides that span the entire length of the coding region of that gene. To reduce 
substantially the rate of false positives, each of these oligonucleotides is paired with a 
second mismatch oligonucleotide in which the central base in the sequence has been 
replaced by a different base. As in the cDNA approach, fluorescently labeled probes are 
generated from test and reference samples in order to carry out comparative gene 
expression profiling. After cDNA amplification, the differential fluorescent signal is 
detected with a laser scanning system and provides a map of the alterations in the 
transcriptional profile between the test and reference samples that are being compared. 
Dynamic analysis and further sophistication is added to such oligonucleotides array 
capabilities by the techniques briefly discussed in Section 2.6. The molecular classification of 
cancers is of immediate importance to both cancer diagnosis and therapy. Tumors with 
similar histologic appearance quite often have markedly different clinical response to 
therapy. Such variability is a reflection of the underlying cell line and molecular 
heterogeneity of almost any tumor. Gene expression profiling has been successfully 
employed for molecular classification of cancers. It would seem from available data that 
each patient has her/his own molecular identity signature or fingerprint (Mohr et al 2002). 
Thus, Ross et al. (2000) reported the gene expression analysis in 60 cancer cell lines utilized 
in the Developmental Therapeutics Program by the National Cancer Institute (NCI) at NIH 
(Bethesda, MD, USA); the report also stated that cell lines could be grouped together 
according with the organ type and specific expression profiles corresponded to clusters of 
genes. Similar findings were reported for ovarian and breast cancers; in the latter case, Perou 
et al. (2000) reported that specific epithelial cell line genes clustered together and are 
relevant in breast cancer subdivision into the basal- like and luminal groups. On the other 
hand, the eventual use of microarray technologies for clinical applications will involve the 
utilization of proteome and tissue arrays in addition to gene expression profiling by cDNA 
microarrays and oligonucleotides arrays. Thus, tissue markers revealed unexpected 
relationships, as in the case of gene expression analysis of small-cell lung carcinoma, 
pulmonary carcinoid tissue and bronchial epithelial tissue culture (Anbazhagan et al 1999). 
Because a single biomarker has serious limitations for clinical applications there is a need for 
a battery of disease biomarkers that would provide a much more accurate classification of 
cancers. High-density screening with microarray technologies is therefore valuable in 
pharmacogenomic (individualized therapy), toxicogenomic, as well as in clinical - 
diagnostic investigations.  
2.3 Proteome arrays 
In a manner similar to the transcriptome, the proteome does undergo both qualitative and 
quantitative changes during pathogenesis, and this is also true in carcinogenesis. Proteome 
array-based methodologies involve either proteins or protein-binding particles (DNA, 
RNAs, antibody, or other ligands). Utilizing such proteome arrays one can respectively 
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study either differential protein expression profiling or protein-ligand interaction screening 
under specified, or selected, physiopathological conditions. According to Kodadek (2001), 
these two classes of practical applications of proteome arrays are respectively defined as 
protein function and protein-detecting arrays. A protein-detecting array may consist of an 
arrayed set of protein ligands that are employed to profile gene expression and therefore 
make visible ‘proteosignatures’ characterizing a selected cellular state or phase. In view of 
the potential clinical importance of a proteomic survey of cancers, the ‘hunt’ is now on for 
such proteosignatures of cancer cells but the amount of data reported to date is still quite 
limited. Already, the coupling of proteome arrays with high-resolution chromatography 
techniques followed by mass spectrometry has provided powerful analytical tools with 
which one can profile the protein expression in cancer cells. For example, a ProteinChipTM 
(Ciphergen Inc, Fremont, CA, USA) was successfully utilized to investigate the proteome of 
prostate, ovarian, head and neck cancer cells (von Eggeling et al 2000). Such methods 
identified protein fingerprints from which cancer biomarkers can also be obtained. A 
reverse proteome array was also reported in which many extracted proteins from a patient 
sample are ‘printed’ onto a flat, solid support (Paweletz et al 2001); this reverse system was 
then utilized to carry out a biochemical screening investigation of the signaling pathways in 
prostate cancer. Through such investigations it was found that the carcinoma progression 
was positively correlated with the phosphorylation state of Akt and negatively correlated 
with ERK pathways; furthermore, the carcinoma progression was positively correlated with 
the suppression of the apoptotic pathways, a finding which is consistent with the more 
detailed, recent reports on cyclin CDK2 and transcriptional factors affected by CDK2 that 
will be discussed in Section 4. Immunophentotyping of leukemias with antibody 
microarrays was also reported (Belov, de la Vega, dos Remedios, et al 2001), and does 
provide an increased antigen differentiation (CD) in leukemia processing. 
2.4 Tissue arrays 
The logical step after the identification of potential cancer markers through genomic and/or 
proteomic array analysis is the evaluation of such cancer markers by tissue arrays/ tissue 
chips for diagnostic, prognostic, toxicogenomic and therapeutic relevance. Such tissue 
microarrays (TMAs) were often designed to contain up to 1000 sections of 5micron thick 
sections, usually chemically--fixed and arrayed upon a glass slide. TMAs allow large-scale 
screening of tissue specimens and can be utilized, for example, for the pathological 
evaluation of molecular irreversible changes that are important for cancer research and 
treatment. Therefore, they can speed up the process of translating experimental, or 
fundamental, discoveries into clinical practice and improved cancer treatments. 
TMAs have been utilized in cancer research in conjunction with fluorescence in situ 
hybridization (FISH), to analyze in parallel the gene amplification in multiple tissue 
sections thus allowing the researchers to map the distribution of gene amplification 
throughout an entire tumor. This also allowed the monitoring of changes in gene 
amplification during the cancer progression (Bubendorf et al 1999). Furthermore, utilizing 
immunohistochemical staining of tissue arrays it was possible to measure the protein levels 
in tumor specimens. Thus, topoisomerase II alpha was reported to be highly expressed in 
patients with the poorest prognosis in oligodendrogliomas (Miettinen et al 2000). TMAs 
may become a clinical validation, as well as a ‘global’ tool; thus, recent studies reported this 
technique to be highly efficient for the identification of molecular (irreversible) alterations 
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during cancer initiation and progression (Lassus et al 2001). A pathologist might, however, 
object that the tissue microarray provides only a partial analysis of the tumor. The array-
based technologies briefly described here provide powerful means for functional analyses of 
cancer and other complex diseases. Undoubtedly, much more can, and will be, done with 
proteome or tissue arrays combined with other state-of-the-science spectroscopic techniques 
as suggested in the following Sections 2.5, 2.6, 4 and 6.2.  
The following three Sections 2.5 and 2.6 and 6.2 will illustrate how advanced, ultra-fast and 
super-sensitive techniques can be used in conjunction with either nucleic acids or proteome 
arrays to both speed up thousand-fold the microarray data collection (for nucleic acids, 
proteins, ligand-binding, etc.) and also increase sensitivity to its possible limit--that of single 
molecule detection. 
2.5 Fluorescence correlation spectroscopy and fluorescence cross—correlation 
spectroscopy: applications to DNA hybridization, PCR and DNA binding 
In the bioanalytical and biochemical sciences Fluorescence Correlation Spectroscopy (FCS) 
techniques can be utilized to determine various thermodynamic and kinetic properties, such 
as association and dissociation constants of intermolecular reactions in solution (Thompson, 
1991; Schwille, Bieschke and Oehlenschläger, 1997). Examples of this are specific 
hybridization and renaturation processes between complementary DNA or RNA strands, as 
well as antigene-antibody or receptor-ligand recognition. Although of significant functional 
relevance in biochemical systems, the hybridization mechanism of short oligonucleotide 
DNA primers to a native RNA target sequence could not be investigated in detail prior to 
the FCS/FCCS application to these problems. Most published models agree that the process 
can be divided into two steps: a reversible first initiating step, where few base pairs are 
formed, and a second irreversible phase described as a rapid zippering of the entire 
sequence. By competing with the internal binding mechanisms of the target molecule such 
as secondary structure formation, the rate-determining initial step is of crucial relevance for 
the entire binding process. Increased accessibility of binding sites, attributable to single-
stranded open regions of the RNA structure at loops and bulges, can be quantified using 
kinetic measurements (Schwille, Oehlenschläger and Walter, 1996). 
The measurement principle for nearly all FCS/FCCS applications is based so far upon the 
change in diffusion characteristics when a small labeled reaction partner (eg, a short nucleic 
acid probe) associates with a larger, unlabeled one (target DNA/RNA). The average diffusion 
time of the labeled molecules through the illuminated focal volume element is inversely 
related to the diffusion coefficient, and increases during the association process. By calibrating 
the diffusion characteristics of free and bound fluorescent partner, the binding fraction can be 
easily evaluated from the correlation curve for any time of the reaction. This principle has been 
employed to investigate and compare the hybridization efficiency of six labeled DNA 
oligonucleotides with different binding sites to an RNA target in a native secondary structure 
(Schwille, Oehlenschläger and Walter, 1996). Hybridization kinetics was examined by binding 
six fluorescently labeled oligonucleotide probes of different sequence, length and binding sites 
to a 101-nucleotide-long native RNA target sequence with a known secondary structure. The 
hybridization kinetics was monitored and quantified by FCS, in order to investigate the overall 
reaction mechanism. At the measurement temperature of 40°C the probes are mostly 
denatured, whereas the target retains its native structure. The binding process could be 
directly monitored through diffusional FCS analysis, via the change in translational diffusion 
time of the labeled 17-mer to 37-mer oligonucleotide probes HS1 to HS6 upon specific 
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hybridization with the larger RNA target. The characteristic diffusion time through the laser-
illuminated focal spot of the 0.5 µm-diameter objective increased from 0.13 to 0.20 ms for the 
free probe, and from 0.37 to 0.50 ms for the bound probe within 60 min. The increase in 
diffusion time from measurement to measurement over the 60 min could be followed on a PC 
monitor and varied strongly from probe to probe. HS6 showed the fastest association, while 
the reaction of HS2 could not be detected at all for the first 60 min. Thus, FCS diffusional 
analysis provides an easy and comparably fast determination of the hybridization time course 
of reactions between complementary DNA/RNA strands in the concentration range from 10-10 
to 10-8 M. The FCS-based methodology also permits rapid screening for suitable anti-sense 
nucleic acids directed against important targets like HIV-1 RNA with low consumption of 
probes and target. Because of the high sensitivity of FCS detection, the same principle can be 
exploited to simplify the diagnostics for extremely low concentrations of infectious agents like 
bacterial or viral DNA/RNA. By combining confocal FCS with biochemical amplification 
reactions like PCR or 3SR, the detection threshold of infectious RNA in human sera could be 
dropped to concentrations of 10-18 M (Walter, Schwille and Eigen, 1996; Oehlenschläger, 
Schwille and Eigen, 1996). The method allows for simple quantification of initial infectious 
units in the observed samples. The isothermal Nucleic Acid Sequence-Based Amplification 
(NASBA) technique enables the detection of HIV-1 RNA in human blood-plasma (Winkler, 
Bieschke and Schwille, 1997). The threshold of detection is presently down to 100 initial RNA 
molecules per milliliter by amplifying a short sequence of the RNA template (Schwille, 
Oehlenschläger and Walter, 1997). The NASBA method was combined with FCS, thus 
allowing the online detection of the HIV-1 RNA molecules amplified by NASBA 
(Oehlenschläger, Schwille and Eigen, 1996). The combination of FCS with the NASBA reaction 
was performed by introducing a fluorescently labeled DNA probe into the NASBA reaction 
mixture at nanomolar concentrations, hybridizing to a distinct sequence of the amplified RNA 
molecule. After having reached a critical concentration on the order of 0.1 to 1.0 nM (the 
threshold for single-photon excitation / FCS detection is ~0.1 nm), the number of amplified 
RNA molecules could be determined as the reaction continued its course. Evaluation of the 
hybridization/extension kinetics allowed an estimation of the initial HIV-1 RNA concentration 
present at the beginning of amplification. The value of the initial HIV-1 RNA number enables 
discrimination between positive and false-positive samples (caused, for instance, by carryover 
contamination). This possibility of sharp discrimination is essential for all diagnostic methods 
using amplification systems (PCR as well as NASBA). The quantification of HIV-1 RNA in 
plasma by combining NASBA with FCS may be useful in assessing the efficacy of anti-HIV 
agents, especially in the early infection stage when standard ELISA antibody tests often 
display negative results. Furthermore, the combination of NASBA with FCS is not restricted 
only to the detection of HIV-1 RNA in plasma.  
On the one hand, the diagnosis of Hepatitis (both B and C) remains much more challenging. 
On the other hand, the number of HIV, or HBV, infected subjects worldwide is increasing at 
an alarming rate, with up to 20% of the population in parts of Africa and Asia being infected 
with HBV. In contrast to HIV, HBV infection is not particularly restricted to the high-risk 
groups. 
Multi-photon (MPE) NIR excitation of fluorophores--attached as labels to biopolymers like 
proteins and nucleic acids, or bound at specific biomembrane sites-- is one of the most 
attractive options in biological applications of FCS. Many of the serious problems 
encountered in spectroscopic measurements of living tissue, such as photodamage, light 
scattering and auto-fluorescence, can be reduced or even eliminated. FCS can therefore 
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provide accurate in vivo and in vitro measurements of diffusion rates, “mobility” parameters, 
molecular concentrations, chemical kinetics, aggregation processes, labeled nucleic acid 
hybridization kinetics and fluorescence photophysics/ photochemistry. Several 
photophysical properties of fluorophores that are required for quantitative analysis of FCS 
in tissues have already been widely reported. Molecular “mobilities” can be measured by 
FCS over a wide range of characteristic time constants from ~10-3 to 103 ms. 
Novel, two-photon NIR excitation fluorescence correlation spectroscopy tests and preliminary 
results were obtained for concentrated suspensions of live cells and membranes (Baianu et al, 
2007). Especially promising are further developments employing multi-photon NIR excitation 
that could lead, for example, to the reliable detection of cancers using NIR-excited 
fluorescence. Other related developments are the applications of Fluorescence Cross-
Correlation Spectroscopy (FCCS) detection to monitoring DNA- telomerase interactions, DNA 
hybridization kinetics, ligand-receptor interactions and HIV-HBV testing. Very detailed, 
automated chemical analyses of biomolecules in cell cultures are now also becoming possible 
by FT-NIR spectroscopy of single cells, both in vitro and in vivo. Such rapid analyses have 
potentially important applications in cancer research, pharmacology and clinical diagnosis. 
2.6 Near infrared microspectroscopy, fluorescence microspectroscopy and infrared 
chemical imaging of single cells 
Novel methodologies are currently being evaluated for the chemical analysis of embryos 
and single cells by Fourier Transform Infrared (FT-IR), Fourier Transform Near Infrared 
(FT-NIR) Microspectroscopy, Fluorescence Microspectroscopy. The first FT-NIR chemical 
images of biological systems approaching 1micron (1μm) resolution were reported (Baianu, 
2004; Baianu et al 2004), and FT-NIR spectra of oil and proteins were obtained under 
physiological conditions for volumes as small as 2μm3. Related, HR-NMR analyses of oil 
contents in somatic embryos were presented with nanoliter precision. Therefore, 
developmental changes may be monitored by FT-NIR with a precision approaching the 
picogram level when adequately calibrated by a suitable primary analytical method.  
Indeed, detailed chemical analyses are now becoming possible by FT-NIR Chemical 
Imaging and Microspectroscopy of single cells. The cost, speed and analytical requirements 
are fully satisfied by FT-NIR spectroscopy and microspectroscopy for a wide range of 
biological specimens. These techniques were also suggested to be potentially important in 
functional genomics and proteomics research (Baianu et al 2004) through the rapid and 
accurate detection of high-content microarrays (HCMA). Multi-photon (MP), pulsed 
femtosecond laser NIR Fluorescence Excitation techniques were shown to be capable of 
single molecule detection (SMD). Thus, microspectroscopic techniques allow for most sensitive 
and reliable quantitative analyses to be carried out both in vitro and in vivo. In particular, MP 
NIR excitation in FCS allows not only single molecule detection, but also non-invasive 
monitoring of molecular dynamics and the acquisition of high-resolution, submicron imaging 
of femtoliter volumes inside functional cells and tissues. Such ultra-sensitive and rapid NIR-
FCS analyses have therefore numerous potential applications in biomedical research areas, 
clinical diagnosis of viral diseases, cancers and also in cancer therapy. 
3. Mapping interactome networks 
Mapping protein-protein interaction networks, or charting the global interaction maps, that 
correspond through translation to entire genomes is undoubtedly useful for understanding 
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cellular functions, especially when such databases can be integrated into a wide collection of 
biologically relevant data. A prerequisite for any ‘ab initio’ determination of a selected 
protein interactome network is to clone the open reading frames (ORFs) that encode each 
protein present in the selected network. Note, however, that all current analyses involve the 
assumption of a model together with some ‘hidden’, or implicit, assumptions about sampling, 
‘noise’ levels, or uniformity/ accuracy in the database, and therefore, the ‘ab initio’ claim is 
subject to the restrictions imposed by such additional assumptions. More than 20,000 of 
publicly accessible, full ORF clones have been already collected for human and mouse 
protein-coding genes in the Mammalian Genome Collection (MGC; http://mgc.nci.nih.gov). 
This community resource enables the next stages of human interactome analysis that will be 
directed at obtaining a reliable map of the entire human protein interactome. An additional, 
12,500 ORFs are now available from the Dana Farber Cancer Institute in Boston (USA) from 
high-throughput, yeast two-hybrid (Y2H) analyses. A disconcerting aspect of the latest 
human (partial) interactome studies by different methods is the little apparent overlap of the 
new human interaction datasets with each other and/or with previously reported data. This 
aspect will be further addressed later in this section; the principal cause for the lack of 
overlap is likely to be caused by the low (<20%) overall coverage of the protein-protein 
interactions selected in such studies. A possible solution to this problem has been suggested 
(Warner et al 2006): several groups cooperating to produce ‘networks of networks’, 
constructed from separate—but coordinated—interaction mapping projects, ‘each of which 
would target a specific functionality related subset of proteins and interactions’. A more 
effective solution would be, however, to increase the throughput, accuracy and reliability of 
PPI data through improved technologies (such as FCCS, or other techniques already 
proposed in Section 2.5, for example), reduce significantly the cost of such analyses, as well 
as improve the models employed for data analysis. Examples of improved modeling tools 
for this purpose, such as logical, ontological genetics and categorical ones, that are also 
appropriate for assembling the ‘networks of networks…’ as in the previous approach 
suggested by Warner et al. (2006), were presented above in Section 1, and are described in 
further detail in a recent report (Baianu et al 2006) and also in two forthcoming publications 
(Baianu and Poli, 2011; Baianu et al 2010). Interactome network studies are currently 
undertaken by a number of international research teams in the US, Europe and Japan 
(CSH/WT, 2006; Warner et al 2006). These studies are currently undertaken only for 
interactome subnetworks because of both technique and funding limitations. The organisms 
studied were: yeast (Saccharomyces cerevisiae), worm (Caenorhabditis elegans), fruitfly 
(Drosophila melanogaster) and humans. Proteome networks were investigated for several, 
specific, biological processes such as: DNA degradation, ubiquitin conjugation, 
multivesicular formation, intracellular membrane traffick, signal transduction/ TNF 
tumor necrosis and NFB mediated pathways, and early stages of T-cell signaling (for a 
brief summary note the recent review by Warner et al 2006, and references cited therein). 
Such challenging studies face both methodological problems such as limited sampling (Han 
et al 2006) and consideration of only pairwise (‘binary’) protein-protein interactions, and also 
the more serious technical problem of false-positive interactions in the presence of a 
significant ‘noise’ levels associated with the experimental technologies and design currently 
employed in such studies. Such limitations should be borne in mind (Han et al 2006) when 
global topology predictions are made for the whole interactome based on partial, 
incomplete data obtained for subnetworks that may contain less than 20% of the entire 
interactome network. On a more optimistic note are the recent attempts at comparing the 
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cancer protein, human interactome (sub) networks with normal human interactome 
networks that involve multiple protein-protein interactions (Jonsson and Bates, 2006). The 
latter studies reduced the ‘noise’ level in the human protein interaction data by employing 
an orthology-based method described previously by Jonsson et al. (2006). This method 
claims to reduce the ‘noise’ level in protein-interaction (PPI) data by identifying putative 
interactions based on homology to experimentally determined interactions in a range of 
different species; both the DIP (Salwinsky et al 2004) and the MIPS, Mammalian Protein—
Protein Interaction (Pagel et al 2005) databases were utilized. Furthermore, the complete 
interactome data set that was employed is available as Supplementary Material from loc. cit. 
The conclusions was drawn that cancer proteins have an increased frequency of protein-
protein interactions in comparison with the proteins that were studied in normal cells, and 
this was interpreted as evidence “indicating an underlying evolutionary pressure to which cancer 
genes, as genes of central importance are subjected.” It remains to be seen, however, if human 
interactome studies-- which occur with increasing frequency-- have indeed overcome the 
sampling objections raised by Han et al. (2006). The more extensive interactome data and 
analysis—though still quite limited- that has been reported to date is readily available and 
includes the following: Y2H (partial data-based) interactome maps for C. elegans (Li et al 
2004) and Drosophila melanogaster (Giot et al 2003; Formstecher et al 2005), and also proteome 
maps obtained by co-affinity purification followed by mass spectrometry analysis in yeast- 
Saccharomyces cerevisiae (co-AP/MS: Gavin et al 2002; Ho et al 2002; Han et al 2004). The 
reports on the microbial transcriptional regulation network of Escherichia coli (Shen-Orr et al 
2002) and on Helicobacter pylori protein complexes in the proteome map (Terradot et al 2004) 
are also worthile mentioning in this context. A first-draft of the human interactome has also 
been reported (Lehner and Fraser, 2004); although this human interactome map does not 
seem to have been included in the computational investigations of Han et al. (2006), it 
remains to be verified, or validated, by further extensive studies with improved technology 
and adequate models for a more comprehensive data analysis. The comprehensive two-
hybrid analysis for exploring the protein interactome network was previously reported by 
Ito et al. (2001). Alternative interaction mapping strategies have also been developed over 
the last five years. An example is the tandem affinity purification (TAP) in conjunction with 
liquid chromatography tandem mass spectrometry (LC-MS/MS; see, for example, Gavin et 
al 2006). Such methods have, however, both advantages and limitations. An interesting, new 
approach to the determination of protein complexes has been developed that involves a 
combination of fluorescence spectroscopy with peptide microarrays (Stoevesandt, cited in 
Warner 2006); this methodology was then applied to investigate T-cell signaling. 
4. Cell cyclins expression and modular cancer interactome networks 
Carcinogenesis is a complex process that involves dynamically inter-connected biomolecules 
in the intercellular, membrane, cytosolic, nuclear and nucleolar compartments that form 
numerous inter-related pathways referred to as networks. One such family of pathways 
contains the cell cyclins. Cyclins are often overexpressed in cancerous cells (Dobashi et al 
2004). 
Our novel theoretical analysis based on recently published studies of cyclin signaling, with 
special emphasis placed on the roles of cyclins D1 and E, suggests novel clinical trials and 








Cyclins are proteins that link several critical pro-apoptotic and other cell cycling/division 
components, including the tumor suppressor gene TP53 and its product, the Thomsen- 
Friedenreich antigen (T antigen), Rb, mdm2, c-Myc, p21, p27, Bax), which all play major 
roles in carcinogenesis of many cancers. Cyclin-dependent kinases (CDK), their respective 
cyclins, and inhibitors of CDKs (CKIs) were identified as instrumental components of the 
cell cycle-regulating machinery. CDKs are enzymes that phosphorylate several cellular 
proteins thus ‘fueling’ the sequential transitions through the cell division cycle. In 
mammalian cells the complexes of cyclins D1, D2, D3, A and E with CDKs are considered 
motors that drive cells to enter and pass through the “S” phase. Cell cycle regulation is a 
critical mechanism governing cell division and proliferation, and is finely regulated by the 
interaction of cyclins with CDKs and CKIs, among other molecules (Morgan et al 1995).  
It was also reported that CDKs have another key role –the coordination of cell cycle 
progression with responses to possible DNA-damage that could, if unchecked or unfixed, 
lead to a lack of genomic integrity marking the onset of cell disease including cancers 
(Huang et al 2006 in Science). The S-phase is thought to be the most vulnerable interval of 
the cell cycle because during this interval all of 3 billion DNA bases of the human genome 
must be replicated precisely in the sense of ‘carbon copies’ being made of the existing DNA 
strands, without any breaks in the sequence or base substitutions of the copied/replicated 
strands. Therefore, this correct replication process controls the cell’s survival, especially 
under genotoxic conditions such as those caused for example by mutagens or X-ray and 
gamma-radiation. Furthermore, Huang et al. (2006) reported that CDK mediated the 
phosphorylation of the FOXO1 transcriptional activator of the proapoptotic genes during 
the S-phase; when DNA damage occurs either before or during the S-phase, a complex 
network is activated in the cell which ‘silences’ CDK thereby either delaying or 
stopping/arresting the cell cycle progression. This may allow the cell to repair the DNA 
damage by recombination involving BRCA2 and survive. However, if this is not possible 
because the DNA damage was too great/irreparable, then FOXO1 would trigger apoptosis 
(cell death). It was proposed that during the unperturbed (normal) S-phase CDK2 
phosphorylates FOXO1 at the Serine249 residue in the cell nucleus, which then results in the 
transfer and sequestering of the FOXO1 in the cytoplasm, where it is well--separated from 
the proapoptotic genes, the ‘target’ of FOXO1 action. 
Moreover, the CDK-mediated phosphorylation of BRCA2 during the unperturbed S-phase 
renders inactive the DNA recombination. On the other hand, when DNA becomes damaged, 
CDK2 is inhibited through the Cdc25A pathway, with the consequence of a dephosphorylated 
FOXO1 which then remains in the cell nucleus and is able to activate the proapoptotic genes, 
unless BRCA2 is able to induce DNA recombination and repair in time to prevent apoptosis. 
The steps that follow are then as explained above: either DNA repair and continued cell 
cycling, or apoptosis induced by FOXO1. There are still several important questions regarding 
the entire process that need to be answered before the FOXO1 and CDK2 mechanisms of 
action can be translated into successful clinical trials based on such knowledge. 
A positive correlation has been noticed between over-expression of several cell--cycle 
proteins and unfavorable prognoses and outcomes in several different cancer types (van 
Diest et al 1995; Fukuse et al 2000). In human lung tumors and soft tissue sarcomas, it was 
discovered that cyclin A/cdk2 complex expression and kinase activity were reliable 
predictors of proliferation and unfavorable prognosis, thereby further substantiating the 
epidemiological factors of cyclin signaling (Dobashi et al 2003; Noguchi et al 2000).  
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Fig. 1. Gene database of Cyclin-D1; Source: PBD website: 
http://www.dsi.univ-paris5.fr/genatlas/fiche.php?symbol=CCND1 
4.2 The p27 and p21 proteins 
The proteins p27 and p21 were reported to be implicated in cyclin regulation and cancer 
development (Fig. 2). Mouse embryonic fibroblasts that were deficient for p27 and p21 were 
found to contain less cyclin D1 (Hashemolhosseini S, Nagamine Y, Morley SJ, et al., 1998). 
and D2 (Cheng et al 1999) as well as cyclin D3 (Bagui et al 2000) than controls. Similarly, 
mammary glands of p27-deficient mice were shown to possess decreased cyclin D1 levels 
(Muraoka et al 2001). It has been demonstrated in vivo that p27 is necessary for maintaining 
proper levels of cyclins D2 and D3, and this dependency on p27 is common to a wide 
variety of cells/tissues in vivo. Regarding the molecular interaction between p27 and D-
cyclin, CDK4 is a clear candidate as a mediating molecule (Bryja et al 2004). Cells employ 
CDK4/6– cyclin D complexes to flexibly titrate p27 from the complexes containing CDK2, 
and thereby they control their proliferation. However, mutual dependency between cyclin D 
and p27 serves also some yet unidentified function in differentiation-related processes. 
Thus, loss of p27 not only causes unrestricted growth due to inefficient inhibition of CDK2–
cyclin E/A, but may also elicit a decrease in levels of D-type cyclins, resulting in 
differentiation defects. Upon ablation of cyclin D, cells lose their ability to titrate p27 from 
CDK2–cyclin A/E complexes and proliferation is suppressed. However, defects in 
differentiation caused by the absence of D-cyclin are reminiscent to defects produced by the 
absence of p27 (Bryja et al 2004). When the changes in levels of p27 and/or D-type cyclins 
occur, an equilibrium alteration could result between proliferation/differentiation processes 
that may in the end result in tumorigenesis (Bryja et al 2004). 
4.3 D1 vs. E- cyclins 
The D-type and E-type cyclins control the G1 → S phase transition during normal cell 
cycling and are important components of steroid- and growth factor-induced mitogenesis in 
breast epithelial cells (Sutherland and Musgrove, 2004). Cyclin D1 null mice are resistant to 
breast cancer that is induced by the neu and ras oncogenes, which suggests a pivotal role for 
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cyclin D1 in the development of some mammary carcinomas (Sutherland and Musgrove, 
2004). Cyclin D1 and E1 are usually overexpressed in breast cancer, with some association 
with adverse outcomes, which is likely due in part to their ability to confer resistance to 
endocrine therapies. The consequences of cyclin E overexpression in breast cancer are 
related to cyclin E’s role in cell cycle progression, and that of cyclin D1 may also be a 
consequence of a role in transcriptional regulation (Sutherland and Musgrove, 2004). One 
critical pathway determining cell cycle transition rates of G1 → S phase is the cyclin/cyclin-
dependent kinase (Cdk)/ p16Ink4A/ retinoblastoma protein (pRb) pathway (Sutherland 
and Musgrove, 2004). Alterations of different components of this particular pathway are 
very ubiquitous in human cancer (Malumbres and Barbacid, 2001). There appears to be a 
certain degree of tissue specificity in the genetic abnormalities within the Rb pathway. A 
model relating Rb to cyclin control in the overall scheme of pro-apoptotic behavior is shown 
in Fig. 2.  
In breast cancer these abnormalities include the over-expression of cyclins D1, D3 and E1, 
the decreased expression of the p27Kip1 CKI and p16Ink4A gene silencing through 
promoter methylation. These aberrations occur with high frequency in breast cancer, as each 
abnormality occurs in ~40% of primary tumors. This fact implicates a major role for the loss 
of function of the Rb pathway in breast cancer. Cyclin D1 is the product of the CCND1 gene 
and was first connected to breast cancer after localization of the gene to chromosome 11q13, 
a region commonly amplified in several human carcinomas, including ~15% of breast 
cancers (Ormandy et al 2003). The fact that cyclin D1 was overexpressed at the mRNA and 
protein levels in 50% of primary breast cancers have caused cyclin D1 to be considered one 
of the most commonly over-expressed breast cancer oncogenes (Gillett et al 1994). Although 
cyclin E1 locus amplification is rare in breast cancer, the protein product is overexpressed in 
over 40% of breast carcinomas (Loden et al 2002). Cyclin D1 is pre-dominantly 
overexpressed in ERC tumors, and cyclin E overexpression is confined to ER¡ tumors (Gillett 
et al 1994; Loden et al 2002). The overexpression of several cell cycle regulators has been 
strongly associated with apoptotic-like behavior, as well as frank apoptosis, in cancer cells, 
which include c-Myc, E2F-1 and HPV. Apoptosis and its connection to cell cycle-related 
proteins is of interest therapeutically, as these types therapies could ultimately lead to the 
cancer cell annihilation via apoptosis. Recently, a shift has occurred, changing the focus of 
chemotherapy from exploration of agents that cause cell growth arrest to those that favor 
apoptosis.  
5. Biomedical applications of microarrays in clinical trials 
5.1 Microarray applications to gene expression: identifying signaling pathways 
Changes in homeostasis can be followed through various experimental strategies that 
monitor gene expression profiling, for example, by employing high-throughput microarray 
technology. This section discusses briefly the successful use of microarray technology in 
RNA expression studies aimed at identifying signaling pathways that are regulated by key 
genes implicated in carcinogenesis/ tumorigenesis. A primary objective of tumor-profiling 
experiments is to identify transcriptional changes that may be the cause of the transition 
from the normal to the tumor phenotype. Such changes may, however, occur also as a 
consequence of various neoplastic transformation(s). More importantly, this approach may 
allow the identification of molecular fingerprints that can be utilized for the classification of 
different tumor types, and are therefore valuable diagnostic molecular tools in cancer 
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Fig. 2. Pro-Apoptotic Cancer Cycling Model: an update based on the previous model of 
Aguda et al. (2003). 
patients. For example, Alizadeh et al. (2000) have successfully used such an approach to 
identify molecularly distinct subclasses of diffuse large B-cell lymphoma that could not be 
distinguished by conventional diagnostic tools. In another study, a molecular fingerprint 
comprising approximately 50 genes has been isolated from a total of over 6,000, and this 
fingerprint can reliably differentiate between acute myeloid leukemia and acute 
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5.1.1 Identification of specific transcriptional targets in cancer 
The approach requires, however, multiple independent experiments with several large 
groups of samples in order to enable one to reliably and reproducibly separate the 
biologically relevant changes from false ones that may occur as a result of the genetic 
heterogeneity between individual samples from the same tumor, for example. The two 
examples quoted above were able to reproducibly identify tumor type-specific molecular 
determinants through multiple experiments with various tissue samples. 
A different experimental approach to the one presented above is, however, needed for 
identifying specific targets such as defined genes that are implicated in cancer progression; 
this involves monitoring changes in transcriptional profile that occur as a result of 
modulation of the expression level of the defined gene, or genes, selected for such studies. 
The altered expression profile can be viewed as a ‘blueprint’ by which the defined gene 
controls its cellular function. The transcriptional profiles are thus employed to define 
downstream signaling pathways that have been previously validated through other techniques 
such as differential display Tanaka et al (2000) and serial analysis of gene expression Yu et 
al. (1999). This approach combined with microarray technology allows the simultaneous 
identification of all potential targets. Its only drawback is the reliance upon the prior 
knowledge of the selected genome for such investigations. The caveat is, however, that the 
investigator who employs this approach needs also to devise additional experiments in 
order to confirm that genes identified with the microarray are indeed physiologically relevant 
targets.  
5.1.2 Identification of downstream transcriptional targets of the BRCA1 tumor-
suppressor gene 
The breast and ovarian cancer susceptibility gene BRCA1 is probably the most studied gene 
in the breast cancer field because of its clinical significance and multiple functions. BRCA1 
was shown to be mutated in the germ line of women with a genetic predisposition to either 
breast or ovarian cancer Mikki et al (1994). Most mutations identified reported have resulted 
in the premature truncation of the BRCA1 protein. BRCA1 is known to encode a 1863 amino 
acid phosphoprotein that is predominantly localized to the nucleus, presumably with a 
unique function. Protein sequence analysis identified a C-terminal BRCT motif, which was 
then postulated to play a role in cell cycle checkpoint control in response to DNA damage 
Koonin EV, Altschul and Bork (1996). Consistent with this postulated role, BRCA1 becomes 
hyperphosphorylated in response to various agents that damage DNA such as /X--ray-
irradiation, an effect that was reported to be partially mediated by chk2 kinases (Lee et al. 
2000). Furthermore, BRCA1 has been shown to be implicated in at least three functional 
pathways: 
 Mediating the cellular response to DNA damage, 
 Acting as a cell cycle checkpoint protein, and 
 Functioning in the regulation of transcription. 
However, the physiological significance of such BRCA1 actions as well as their relationships 
with the function of BRCA1 as a tumor-suppressor gene still remain to be defined. Further 
details are presented next.  
The BRCA1-BARD1 ubiquitin ligase 
As shown above the BRCA1 gene encodes a 1863-amino-acid protein (Miki et al 1994) which 
consists of a RING-finger domain in its terminal N-region, a region that includes a nuclear 
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localization signal and a domain that binds to many cellular proteins, and tandem BRCT 
domains in its C-terminal region. BRCA1 is associated with a diverse range of biological 
processes, such as DNA repair, cell cycle control, transcriptional regulation, apoptosis and 
centrosome duplication. Thus, a specific role has already been postulated for BRCA1 in 
transcriptional regulation. The C-terminal domain of BRCA1 was reported to contain a 
potent transactivation domain when this was fused to a heterologous DNA binding motif 
(Monteiro, August and Hanafusa, 1996). The oligonucleotide array-based expression 
profiling described above in Section 2.2 was employed by Haber (2000) in collaboration with 
Affymetrix Co. to identify the downstream transcriptional targets of the BRCA1 tumor-
suppressor gene in order to define its function (Harkin et al 1999). A known biochemical 
function of BRCA1 is its E3 ubiquitin ligase activity. The following reported observations 
provide only indirect, additional clues to the tumor-suppressor gene function of BRCA1. 
Germ line mutations of BRCA1 were reported for half of breast-ovarian cancer pedigrees 
and for approximately 10% of women with early onset of breast cancer, uncorrelated with 
their family history (Fitzgerald et al 1996). It was also shown in other studies that somatic 
inactivation of BRCA1 is rare in sporadic breast cancers (Futreal P, Liu Q, Shattuck-Eidens D 
et al., 1994) and mutations were reported for approximately 10% of sporadic ovarian 
cancers, therefore suggesting potentially distinct genetic mechanisms for sporadic, breast 
and ovarian cancers (Berchuk et al 1998). The reduced BRCA1 protein expression reported 
for the majority of sporadic breast cancers indicates that epigenetic mechanisms such as those 
described in Section 6 was suggested to play a significant role in regulating the BRCA1 
expression (Wilson et al 1999). Furthermore, a defect was reported in the transcription-
coupled repair of oxidative-induced DNA damage in mouse embryo fibroblasts with 
attenuated BRCA1 function (Gowen et al 1998); this observation would suggest that BRCA1 
plays a more general role in mediating the cellular response to DNA damage. Thus, BRCA1 
has also been reported to be involved in cell cycle checkpoint control, by becoming 
hyperphosphorylated during late G1 and S cell phases, and then changing to transiently 
dephosphorylated early after the M phase (Ruffner and Verma, 1997). Moreover, the BRCA1 
overexpression has been reported to induce a G1/S arrest in human colon cancer cells 
(Somasundaram et al, 1997). By comparison with the cancer regulation model in Figure 2, it 
seems very significant for oncogenesis that BRCA1 is physically associated with the 
transcriptional regulators p53 (Ouichi et al 1998), CtIP (Yu et al 1998), c-Myc (Wang et al 
1998), as well as the histone deacetylases HDAC1 and HDAC2 (Yarden and Brody 1999). 
The physical association of BRCA1 with c-Myc acquires special significance as c-Myc seems 
to be involved in controlling telomerase activity, whereas p53 is involved in DNA-repair, 
cell-cycling and apoptosis. Therefore, in the simplified model presented in Figure 3, one 
should add the BRCA1 links to both p53 and c-Myc in order to facilitate an understanding of 
the BRCA1 possible roles in oncogenesis.  
5.1.3 Selecting gene expression systems 
There are several related problems in studying gene function by expression profiling. For 
example, it has been often reported to be difficult to generate cell lines that overexpress 
genes such as BRCA1, or p53, because their forced overexpression can lead either to 
growth suppression or apoptosis (as shown for example in Figure 3, and at the end of the 
previous section). However, in the case of BRCA1, it was reported that the tet-off inducible 
expression system (Gossen and Bujard 1992) can be utilized to generate cell lines with 
highly regulated inducible expression of BRCA1 (Harkin et al, 1999). This inducible 
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expression system introduces into the cells a chimeric transactivator; the latter consists in 
the tet repressor fused to the VP16 transactivation domain. This chimeric transactivator is 
inactive in the presence of tetracycline, whereas in the absence of tetracycline it can bind 
to promoters that contain the tet operator sequence; the latter sequence is then utilized to 
drive the expression of BRCA1. This expression system has a major advantage in that it 
allows the change in just one parameter involved in the induction of BRCA1. The BRCA1 
induction in one population is the only difference between the genetic backgrounds of the 
two populations that are being compared by oligonucleotides arrays. A number of BRCA1 
transcriptional targets can thus be identified with Affymetrix oligonucleotides arrays, and 
among these, the stress and DNA damage-inducible gene GADD45 was the gene that 
exhibited the greatest degree of differential signal intensity (Harkin et al, 1999). The 
specific target genes thus identified were also verified by Northern blot or quantitative 
reverse transcriptase-PCR analysis in order to confirm induction in response to the 
stimulus, that is, the induction of BRCA1 (Harkin et al, 1999). Total RNA was extracted 
from cells in which the exogenous BRCA1 was either switched off (+ tet) or switched on (– 
tet). Fluorescent images were generated using the Affymetrix human cancer G110 array 
containing approximately 1,700 genes that were previously reported to be implicated in 
cancer; such fluorescent images were then scanned and analyzed. Two lanes were present 
in such images that corresponded to individual arrays hybridized with biotinylated cRNA 
probes and were generated from cells in which exogenous BRCA1 was either induced (+ 
tet) or repressed (- tet). Each gene on the array was represented by 16 probe pairs, one 
being wild-type and one containing a mismatch at the central nucleotide. In such 
fluorescent images, two genes, GADD45 and ATF3 were identified (and confirmed by 
Northern blot analysis) as being the transcriptional targets of the BRCA1 tumor-suppressor 
gene. Furthermore, in this BRCA1 study, the induction of GADD45 by BRCA1 was 
reported to be correlated with the BRCA1-mediated activation of the c-jun N-terminal 
kinase/stress-activated protein kinase JNK/SAPK pathway. Significantly, the activation 
of JNK/SAPK was then shown to be required for the BRCA1-mediated apoptotic cell 
death in this cell line system. This finding suggests an interesting model for the BRCA1-
mediated apoptosis, as presented in some detail by Harkin et al (1999). Most significantly, 
the experimental approach reported by Harkin et al (1999) was indeed able to define 
physiologically relevant target genes. In another recent report, Yu et al (2001) utilized a 
modified version of the tet-off inducible expression system to define the downstream 
transcriptional targets of the p53 tumor--suppressor gene (Yu et al 1999). A total of 34 
genes were identified that exhibited at least a 10-fold upregulation in response to the 
inducible expression of p53. Somewhat surprisingly, there was a marked heterogeneity of 
the response when it was evaluated in different cell lines derived from the same tissue of 
origin. Among the 33 genes studied only nine were found to be induced in a panel of five 
unrelated colorectal cell lines, and 17 were induced in a subset; eight were not induced at 
all in any of the five cell lines examined. This can be interpreted as being due to a high 
degree of cell type specificity. Furthermore, p53 was not absolutely required for induction 
-- for the majority of the genes identified-- in response to either adriamycin or 5-FU. 
Therefore, these agents do not seem to act exclusively through p53, suggesting that there 
is inherent redundancy in the majority of signaling pathways. Such inherent redundancy 
in signaling pathways of cancer, and untransformed, cells might be important in 
understanding the results of clinical trials in cancer treatment with signal transduction 
modulators that will be discussed in the next subsection (5.2). 
www.intechopen.com
 
Oncogenomics and Cancer Interactomics 
 
491 
5.2 Clinical trials with signal transduction inhibitors -- novel anticancer drugs active 
in chemo-resistant tumors 
Recently, there is an increasing number of reports suggesting that human cancers frequently 
involve pathogenic mechanisms which give rise to numerous alterations in signal 
transduction pathways. Therefore, novel therapeutic agents that target specific signal 
transduction molecules or signaling pathways altered in cancer are currently undergoing 
clinical trials often with remarkable results in cancer treatments of patients in which chemo- 
and/or radio- therapy resistant tumors have become apparent. For example, several new 
classes of such anti-cancer drugs are: 
 tyrosine/threonine kinase inhibitors, including: STI-571  
(‘Gleevec’, or Imatinib Mesylate), ZD-1839 (‘Iressa’), OSI-774, and flavopiridol, which 
are ATP-site antagonists and have recently completed phase I and phase II trials (see for 
example, Liu et al, 1999); 
 several other kinase antagonists that are currently undergoing clinical evaluations, 
including UCN-01 and PD184352; 
 other strategies for downmodulating kinase-driven signaling include 17-allyl- amino-17 
demethoxygeldanamycin and rapamycin derivatives. Phospholipase-directed signaling 
may also be modulated by alkylphospholipids. 
 Farnesyltransferase inhibitors, originally developed as inhibitors of ras-driven signals, 
may attain activity by affecting other/or additional targets (see for example, Zujewski, 
Horak, Bol, et al., 2000; End, Smets, Todd, et al., 2001). 
 monoclonal antibodies Herceptin and C225. 
Signal transduction is an efficient method for fine-tuning the development and modeling of 
cancer treatments (Ideker at al., 2001, 2002). There is also a detailed NCI report on clinical 
trial and signal transduction modulators as novel anticancer (Sausville, Elsayed, Monga and 
Kim, 2003). 
5.3 Interactome-transcriptome analysis and differential gene expression in cancer 
It has been claimed that high-throughput yeast-two-hybrid (HT-Y2H) methods will allow a 
systematic approach to functional genomics, by placing individual genes in the global 
context of cellular functions (Mendelsohn and Brent, 1999). One finds that high-throughput 
screening methods such as HT-Y2H have indeed allowed the mapping of the first 
interactomes for three eukaryotes (Giot et al 2003; Li et al 2004; Uetz et al 2000). Because of 
the human interactome’s much larger size and its very high-degree of complexity there will 
be quite high costs and labor involved in obtaining the data necessary, for example, for an 
HT-Y2H mapping of a complete human cell interactome. Furthermore, the complete data 
analysis together with the assembly of the complete interactome network is likely to require 
both conceptual and computational advances, in addition to a significant amount of time 
and collective effort(s) by one or several research teams. In view of the high, potential 
importance of the human interactome for cancer therapy, and also for improved diagnosis 
and ‘rational’ clinical trials, such an effort should now be a top priority. Such an effort 
should also be coordinated with an improved mapping of the complete yeast interactome as 
a model, or test, system. Meantime, there have been since 2005 a few reports of ‘surrogate’, 
or partial, human cancer cell interactomes in the form of predicted maps of human protein 
interaction networks based on partial data and comparative analysis. Such studies 
emphasize even further the need and urgency for the complete mapping of several human 
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cancer cell interactomes. Following the seminal studies of DeRisi et al (1996) that utilized 
cDNA microarray to analize gene expression patterns in human cancer, there have been 
relatively few attempts at deriving hypothetical gene expression patterns in human cancer. 
The first claim of such an attempt was recently made by Wachi, Yoneda and Wu (2005) for 
genes that were differentially expressed in squamous cell lung cancer tissues from five 
patients who had undergone surgical removal of the tumor(s). cRNA samples were 
prepared and hybridized to arrays obtained from Affymetrix® (Hg-U133ATM.). These 
authors were able to carry out paired t-test analyses for each individual patient in order to 
distinguish the genes in which expression levels in their squamous lung cancer cells differed 
from the paired normal lung tissue (control samples) obtained from the same five 
individuals. The authors’ prediction methodology will be briefly discussed in the next 
subsection as some of the details are relevant for the evaluation of these results which were 
the first to be reported for the (hypothetical) interactome—transcriptome analysis of human 
cancer cell data for a group of five patients with the same diagnosed form of (lung) cancer, 
and with the same treatment (tumor removal by surgery). The hypothetical human protein 
interaction maps are a relatively new endeavor (Brown and Jurisica, 2005; Lehner and 
Fraser, 2004) perhaps because they are likely to have many false positives, as well as miss a 
significant fraction of the relevant/real protein-protein interactions. Currently, microarray 
analysis still suffers inherently from relatively high noise levels and the accompanying 
information loss (buried in noise); although this inherent noise problem is partially 
eliminated through multiple replicate analyses, the number of replicates is often limited by 
the availability and the material cost. Another significant problem of such microarray 
projects is the huge amount of data that needs to be processed in order to obtain useable 
information (Claverie, 1999).  
5.3.1 Analysis of human protein-protein interactions (HPPI) and integration of array 
data into a predicted protein-protein interaction network (PPIN)  
Wachi, Yoneda and Wu (2005; WYU05) employed for their human cell data analysis a web-
presented database (OPHID, April 25, 2005) of predicted interactions between human 
proteins (Brown and Jurisica, 2005) based on data for human and other four organisms 
which included the intensely-studied yeast and fruit fly. (OPHID is freely available to 
academic users at http://ophid.utoronto.ca). This protein interaction database listed 16,034 
known human protein interactions obtained from various public protein interaction 
databases, as well as 23,889 additional, predicted interactions which are evaluated using 
protein domains, gene co-expression and Gene Ontology terms. The results can be 
visualized in OPHID using a customized, graph visualization program. The data comprises 
literature-derived human PPI from BIND, HPRD and MINT, “with predictions made from 
Saccharomyces cerevisiae, Caenorhabditis elegans, Drosophila melanogaster and Mus musculus”. 
The genes in the WYU05 array were matched to those in OPHID using gene symbols and 
protein sequences. In this manner, 2137 genes in the WYU05 microarray experiments were 
‘matched to the protein network from OPHID’. These predictions should, however, be 
thought of only as ‘hypotheses’ until they are experimentally validated. On the other hand, 
there is increasing evidence that at least certain PPIs may be conserved through evolution 
(Pagel et al 2004; Wuchty et al 2003). Recently, Sharan et al (2005) claimed that about 50% of 
the protein-protein interactions predicted by using interologs between microorganisms are 
also experimentally validated. The interologs approach might play therefore a role in the 
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partial validation of the HT-Y2H protein network mapping without, however, necessarily 
achieving the claimed, global validation of the predicted (hypothetical) interactome. 
Differentially expressed genes (DEGs) from squamous cell carcinomas (SCCs) were then 
identified as discussed above and their connectivity in the network graph was examined to 
determine their ‘topological’ properties, such as the edge distribution for DEGs in 
comparison with the surrounding graph subnetwork.  
5.3.2 Differentially expressed genes –DEG- results for SCC of human lung 
The genes that are upregulated in SCC were found to exhibit a positive correlation 
(Pearson’s r-coefficient of 0.82) with the number of edges associated with them (Fig. 1a of 
Wachi, Yoneda and Wu 2005), which was interpreted as indicating that DEGs that are 
upregulated in SCC are also highly connected. However, the downregulated genes were 
reported also to have a positive correlation (r = 0.75) to connectivity, albeit slightly lower 
(Fig. 1b of Wachi, Yoneda and Wu, 2005). On the other hand, microarray probesets that 
matched the genes in the protein network (n =-2,137) had a negligible correlation coefficient 
(r =0.06) to link number, proving that the genes on the test microarrays did not contribute to 
bias in the number of links for DEGs in SCC.  
A k-core analysis of DEGs in SCC of the human lung was also carried out (loc. cit.) which 
were reported to measure “how close are the DEGs to the topological ‘center’ of the human PPI 
network”. Based on the k-core analysis, it was concluded that: “the upregulated genes are more 
centrally located in the protein network than the down-regulated genes”. If duplicated and 
validated, such studies would be important as the ‘topological centrality’ of the genes in the 
interactome was previously reported to be associated with the essential functions of the 
genes in the yeast (Jeong et al 2001). Such essential genes, are lethal when mutated, and also 
tend to have high connectivity. Moreover, other genes that are not essential in this sense, but 
provide a vital function in toxin metabolism were reported to have a high number of edges 
associated with the nodes, and to be less well connected than the essential genes in yeast 
(Said et al 2004). Furthermore, a k-core analysis has also been performed on the yeast 
essential genes and they were reported to be global hubs, whereas the non-essential genes 
were not hubs (Wuchty and Almaas, 2005). It was also claimed that these essential, global 
hubs are conserved throughout different species; however, one notes that, thus far, there is 
insufficient data and evidence to prove this claim, or hypothesis. Nevertheless, one may 
consider as a ‘working hypothesis’ that “there should be a core set of genes that needs to be 
maintained throughout the course of somatic evolution in the tumor microenvironment” (Wachi, 
Yoneda and Wu, 2005). This hypothesis is thus consistent with the somatic evolution model of 
cancer. Such conserved genes might be the ‘essential genes’ in cancer cells, and they may 
also have somewhat analogous to the global hub, essential genes reported in yeast (Wuchty 
and Almaas, 2005). DEGs would thus be essential for the survival and proliferation of cancer 
cells in SSC of the human lung, and the upregulated genes would be centrally located in the 
protein network as well as have higher connectivity, perhaps suggesting their possible 
essential role(s) in human (SSC) lung cancer. As this is the first report of a predicted/ 
hypothetical human cancer interactome network one should definitely consider ‘replicating’ 
the reported studies and also evaluating such potentially important findings in the context 
of a complete human cancer interactome (differential) analysis. This possibility that DEGs 
might be essential for the survival and proliferation of cancer cells in SSC of the human lung 
has much too important consequences to be ignored; therefore, it must be thoroughly 
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investigated and also tested with sufficiently extensive, translational genomics and 
transcriptional databases that do not seem to be currently available (Han et al. 2006). Further 
supporting analyses for this conjecture made by Wachi, Yoneda and Wu (2005) are 
considered in the next section. 
5.4 Cancer proteins and the global topology of the human interactome network 
A recent and extensive study of both cancer and non-cancer proteins (Jonsson and Bates, 
2006) was integrated into a validated protein-protein interaction (PPI) network, or 
interactome, of human proteins. In their report, the connectivity properties were 
investigated for all proteins previously shown to be modified as a result of mutations 
leading to cancer (Furteal, et al 2004). A global protein-protein interaction network was then 
constructed by a homology--based method which is claimed to accurately predict protein-
protein interactions. It was then suggested that human proteins that are involved in cancer, 
or ‘cancer proteins’, exhibit a network topology which is substantially different from that of 
other proteins which are considered not to be involved in cancer. Notably, increased 
connectivity was pointed out for cancer proteins involved in the following subnetworks: cell 
growth and apotosis-related, signal transduction (MAPK, TGF-beta, insulin, T-cell and B-cell 
receptor, adipocytokine, cytokine-cytokine interaction), cell motility/cytoskeleton, cell 
communication, adherence junction, focal adhesion, leukocyte migration, antigen processing 
and folding/sorting/degradation. Furthermore, it was proposed that such observations 
‘indicate an underlying evolutionary pressure to which cancer genes, as genes of central importance, 
are subjected.’ Linking these claims with previous proposals by Wuchty and Almaas (2005) 
that globally central proteins form an evolutionary backbone of the proteome and are essential 
to the organism, (and also with the conjecture made by Wachi, Yoneda and Wu, 2005, 
discussed here in Section 5.3.), Jonsson and Bates (2006) suggested that cancer proteins may 
generally be older than the non-cancer ones in evolutionary age. Furthermore, they also 
suggested that the somatically mutated cancer proteins may be of somewhat younger 
evolutionary average age in comparison with those from the germline, as a consequence of 
the evolutionary selection pressure postulated to affect germline mutated proteins. Note 
also that the previous study of (SCC) human lung cancer by Wachi, Yoneda and Wu (2005) 
also reported increased interaction connectivity in differentially expressed proteins in 
human lung cancer tissues.  
6. Epigenomics in mammalian cells and multi-cellular organisms 
6.1 Epigenetic controls 
Upon completion of the US Human Genome Mapping Project and related studies, it became 
increasingly evident that a sequence of 30,000 or so ‘active’ genes that encode and direct the 
biosynthesis of specific proteins could not possibly exhaust the control mechanisms present 
in either normal or abnormal cells (such as, for example, cancer cells). This is even more 
obvious in the case of developing embryos or regenerating organs. Subsequently, more than 
120,000 genes were suggested to be active in the human genome (Nature, 2004). 
Furthermore, specific control mechanisms of cellular phenotypes and processes were 
recently proposed that involve epigenetic controls, such as the specific acetylation <=> de-
acetylation reactions of DNA-bound histones (for an overview article on epigenomics see, 
for example, Scientific American 2003, December issue). Such controls intervene from outside 
the genome but ultimately they also affect gene expression. Therefore, gene profiling 
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techniques would need to be combined with epigenomic tools and analysis in order to gain 
an improved understanding of functional genomics and interactomics. Epigenomic tools 
and novel techniques begin to address the complex and varied needs of epigenetic studies, 
as well as their applications to controlling cell division and growth. Such tools are, therefore, 
potentially very important in medical areas such as cancer research and therapy, as well as 
for improving ‘domestic’ animal phenotypes without involving genomic modifications of the 
organism. This raises the interesting question if ‘epigenomically controlled-growth 
organisms’ (ECGOs) -- to be produced in the future-- would be still argued against by the 
same group of people who currently objects to GMOs, even though genetic modifications 
would be neither present nor traceable in such ECGO organisms?’ 
6.2 Novel tools in epigenomics: rapid and ultra-sensitive analyses of nucleic acid –
protein interactions 
Several novel techniques could also be applied for the highly-selective detection of 
epigenomic changes in mammalian cells related to diseases such as individual types of 
cancer (Jones and Laird, 1999; Plass, 2002) and Alzheimer disease. Such novel tools are 
likely to be utilized in a wide range of applications in biotechnology research related to 
Post-Genomics and Epigenomics. Tumor suppressor genes are transcriptionally silenced 
by promoter hypermethylation that also appears to lead to alterations in chromatin 
structure- a possible mechanism for such repression of the suppressor genes. In contrast 
to the genetic mutation or deletion mechanism of tumor suppressor gene inactivation, 
epigenetic inactivation of tumor suppressor genes would occur via methylation of specific 
DNA regions that could be prevented by DNA methyl-transferase or histone deacetylase 
inhibitors. Aberrant CpG--island methylation has non-random/tumor-type-specific 
patterns (Costello et al 2000). Such patterns can be identified by employing methylation--
specific PCR (MS-PCR; Herman et al 1996), and can also be employed either for tumor 
class prediction by microarray-based DNA methylation analysis (Adorjan et al 2002) or 
for high-throughput microarray-based detection and analysis of methylated CpG islands 
(Yan et al 2002). Hypermethylation profiling is important for both accurate diagnosis and 
the development of optimal strategies in cancer therapy. Gene promoter 
hypermethylation has been reported in both tumors and serum of patients diagnosed with 
several types of cancer: head and neck cancers (Sanchez-Caspedes et al. 2000), 
nasopharyngeal carcinoma (Wong et al. 2002), non-small cell lung cancer (Belinsky et al 
1998; An et al 2002), gastric carcinoma (Lee et al 2002), liver, prostate, bladder and 
colorectal cancers (Wong et al 1999; Jeronimo et al 2002). Substantial efforts are being 
made recently for the development of new methods and tools that are capable of sensitive 
and quantitative DNA methylation analysis, as well as early and accurate diagnosis of 
cancer. Among such tools are: Fluorescent methylation--specific polymerase chain 
reaction assay (FMS-PCR; Goessl et al 2000), SNIRF (Mahmood and Weissleder, 2003), 
indocyanine green-labeling (IGL) for human breast carcinomas (Ntziachristos et al 2000), 
ConLight-MSP (Rand et al 2002), COBRA (Xlong and Laird, 2002), Methylation-Sensitive 
Single Nucleotide Primer Extension (Ms-SnuPE; Gonzalgo and Jones, 1997), DNA 
microarray sensitive detection by Metal-Enhanced Fluorescence (MASD/MEF; Lakowicz, 
2001; Malicka et al 2003 a, b)), and NIR Fluorescence Micro-Spectroscopy (NIRFMS), 
single cancer cell detection (Baianu et al 2004a). Specific molecular markers of cancer 
(Sidransky, 2002) hold the promise to identify those molecular signatures that are unique 
to specific types of cancer, and are essential for the early accurate diagnosis and treatment of 
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cancer. Such novel molecular tools and methodologies could be employed to rapidly and 
accurately identify molecular signatures of cancer and aging-related diseases in 
mammalian cells in culture in order to determine how specific epigenomic mechanisms 
involved in the control of cell division and apoptosis operate throughout the cell cycle. 
Among the specific epigenomic control mechanisms that one could investigate with such 
new tools are: CpG-island methylation, p15 (INK4b) and p16 (INK4a) hyper-methylation 
(in synchronous hepatic carcinoma cells), GSTP1 methylation in non-neoplastic/ 
synchronous cells, as well as histone-deacetylation and its effects on histone- nucleic acid 
interactions in stable synchronous cell populations in culture. Both cancer and aging were 
reported to involve DNA methylation of specific genome regions (van Helden & van 
Helden, 1989; Ahuja et al 1998). Gene expression profiling and epigenomic testing could 
be carried out with both ultra-sensitive, novel human and mouse microarrays. Powerful 
spectroscopic and microspectrosopic techniques can be then employed for the analysis 
and further improvement of such tools for the investigation of nucleic acid--protein 
interactions. 
 
 High-field 2D NMR of protein--protein and protein--nucleic acid interactions 
 NIR Chemical Imaging of protein clusters in cells and single cancer cells in tissue; 
NIR-FMS; SNIRF 
 MEF and FCS/FCCS/ FRET detection of single molecules amplified-ELISA; NASBA 
 Ms-SnuPE; FMS-PCR; Lux TM Fluorogenic Primers*/ RT-PCR*, 
 MyArray TM DNA- Human*, GeneFilters R Human Regular Arrays**. 
 Specific Knock-out or silencing shRNAi’s (SuperArrayTM). 
**The testing of these new tools can be carried out for example with stable and synchronous 
mammalian (human HeLa and mouse) cells in culture. 
Table 1. Techniques under Development and Related Applications that are commercially 
supported *,**. 
7. Conclusions and discussion 
Novel translational oncogenomics research is rapidly expanding with a view to the 
application of new technologies, findings and computational models in both pharmaceutical 
and clinical areas. Sample analyses in recent clinical studies have shown that gene 
expression data can be employed to distinguish between tumor types as well as to predict 
outcomes. Important, potential applications of such results are individualized human cancer 
therapy (Pharmacogenomics) and ‘personalized medicine’. There is clearly a need for 
individualized cancer therapy strategies based on high-throughput microarray information 
recorded for isolated tumor cell lines from stage I through stage III cancer patients. Studies 
of Differential Gene Expression in human cancer cell lines are clearly required for 
developing new strategies for efficient cancer therapies for patients whose tumors have 
developed resistance to existing therapies. Such gene profiling expression, proteomic, 
interactomic and tissue array data is essential for improving the survival rate of stage III 
cancer patients undergoing clinical trials with novel signaling pathway inhibitors/ blocker 
medicines, such as those discussed in some detail in Section 5. Several technologies aimed 
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at future applications in oncogenesis are currently under development both in the direction 
of improved detection sensitivity and increased time resolution of cellular events, with the 
limits of single molecule detection and picosecond time resolution already being reached 
(Sections 2.5, 2.6 and 6.2). The urgency for funding and carrying out the complete mapping 
of a human cancer interactome with the help of such novel, high-efficiency / low-cost and 
ultra-sensitive techniques is pointed out for the first time in the context of recent findings by 
translational oncogenomics and human cancer interactome predictions. 
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